Chemotherapeutic approaches for newly diagnosed hepatoblastoma: Past, present, and future strategies
- 30 May 2012
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 59 (5) , 809-812
Abstract
Surgical resection is the foundation of therapy in hepatoblastoma (HB), yet most patients have unresectable tumors at diagnosis 1. Patients with resectable tumors have event‐free survival (EFS) of 80–90% and can be cured with cisplatin, 5‐fluorouracil, and vincristine. Patients whose tumors are unresectable but without overt metastases at diagnosis have EFS of 60–70%, and many can be rendered resectable without doxorubicin. Children with metastatic disease have fared poorly with 20–50% EFS 1–3, and new approaches for these patients remain desperately needed. Dose intensification of cisplatin and doxorubicin appears beneficial in high‐risk patients. Future treatment strategies, which may be useful, include increasing intensity and/or duration of therapy, developing a maintenance regimen (oral irinotecan), using liver transplantation more often for patients to undergo complete resection, and identifying and incorporating novel agents. A better understanding of the biologic and pathologic factors is critical for predicting tumor behavior and developing more logical risk‐based treatments. Pediatr Blood Cancer 2012; 59: 809–812.Keywords
This publication has 19 references indexed in Scilit:
- Complete Surgical Resection Is Curative for Children With Hepatoblastoma With Pure Fetal Histology: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2011
- Successful Treatment of Childhood High-Risk Hepatoblastoma With Dose-Intensive Multiagent Chemotherapy and Surgery: Final Results of the SIOPEL-3HR StudyJournal of Clinical Oncology, 2010
- Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk HepatoblastomaNew England Journal of Medicine, 2009
- Risk-adapted treatment for childhood hepatoblastomaEuropean Journal of Cancer, 2004
- Treatment of Unresectable and Metastatic Hepatoblastoma: A Pediatric Oncology Group Phase II StudyJournal of Clinical Oncology, 2002
- Hepatoblastoma presenting with lung metastasesCancer, 2000
- Randomized Comparison of Cisplatin/Vincristine/Fluorouracil and Cisplatin/Continuous Infusion Doxorubicin for Treatment of Pediatric Hepatoblastoma: A Report From the Children’s Cancer Group and the Pediatric Oncology GroupJournal of Clinical Oncology, 2000
- Improved outcome for children with hepatoblastomaBritish Journal of Surgery, 1995
- Marked response to preoperative high-dose cis-platinum in children with unresectable hepatoblastomaJournal of Pediatric Surgery, 1991
- Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastomaMedical and Pediatric Oncology, 1985